Mitoxantrone-related acute leukemia by multiple sclerosis: Case report and practical approach by unclear cytopenia;Mitoxantron-assoziierte akute Leukämie bei Multipler Sklerose: Fallbericht und praktisches Vorgehen bei unklaren Zytopenien

Nervenarzt

Volumn 81, Issue 12, 2010, Pages 1483-1489

  Meyer, C ^a   Ansorge, N ^a   Siglienti, I ^a   Salmen, S ^a   Stroet, A ^a   Nuckel H ^b   Duhrsen U ^b   Ritter, P R ^a   Schmidt, W E ^a   Gold, R ^a   Chan, A ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acute myeloid leukemia; Anthracenedione; Cytopenia; Escalating immunotherapy; Nadir; Therapy related acute leukemia

Indexed keywords

MITOXANTRONE;

ACUTE LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; ENDOCARDITIS; HUMAN; MULTIPLE SCLEROSIS; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANALGESICS; HUMANS; LEUKEMIA; MALE; MITOXANTRONE; MULTIPLE SCLEROSIS; THROMBOCYTOPENIA;

EID: 78651362269     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-3041-5     Document Type: Article

References (39)

1. Andersen MK, Larson RA, Mauritzson N et al (2002) Balanced chromosomal abnormalities inv(16) and t(15/17) in therapie-related myelodysplastic syndromes and acute leukemia: report form an international workshop. Genes Chromosomes Cancer 33:395-400
2. Beaumont M, Sanz M, Carli PM et al (2003) Therapy-related acute promyelocytic leukemia. J Clin Oncol 21:2123-2137
3. Beaumont M, Sanz M, Carli PM et al (2003) Therapy-related acute promyelocytic leukemia. J Clin Oncol 21(11):2123-2137
4. Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625
5. Bernitsas E, Wei W, Mikol DD (2006) Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 59(1):206-209
6. Borchmann P, Reiser M (2003) Pixantrone (Novuspharma). IDrugs 6(5):486-490
7. Büchner T, Hiddemann W, Schoch C et al (2001) Acute myeloid leukaemia (AML): treatment of the older patient. Best Pract Res Clin Haematol 14:139-151
8. Büchner T, Hiddemann W, Wörmann B et al (1999) Double induction strategy for acute myeloid leukemia: The effect of high- dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93:4116-4124
9. Carli PM, Sgro C, Parchin-Geneste N et al (2000) Increase of therapy-related leukemia secondary to breast cancer. Leukemia 14:1014-1017
10. Chaplain G, Milan C, Sgro C et al (2000) Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 18:2836-2842
11. Cotte S, Ahsen N von, Kruse N et al (2009) ABC-transporter gene-polymorphism are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132(9):2517-2530
12. Duddy M, Niino M, Adatia F et al (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092-6099
13. Edan G, Miller D, Clanet M et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease ursing MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
14. Ellis R, Boggild M (2009) Therapie-related acute leukemia with mitoxantrone: what is the risk and can we minimize it? Mult Scler 15(4):505-508. Epub 2009 Feb 27
15. Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4(2):219-234
16. Flachenecker P, Zettl UK, Stuke K et al (2007) MS register in Germany: results of the extension phase 2005/2006. Mult Scler 13:87
17. Ghalie RG, Mauch E, Edan G et al (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8:441
18. Harris NL, Jaffe ES, Diebold J et al (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13(2):193-207
19. Hartung HP, Gonsette R, König N et al (2002) Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018-2025
20. Hasan SK, Mays AN, Ottone T et al (2008) Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 112(8):3383-3390. Epub 2008 Jul 23
21. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France
22. Kern W, Haferlach T, Schnittger S et al (2004) Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 22(12):2510-2511
23. Comment in: J Clin Oncol 2005 23(4):926-927
24. Larson RA (2007) Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program 453-459
25. Le Deley MC, Suzan F, Cutuli B et al (2007) Antracyclines, mitoxantrone, radiotherapy and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25(3):292-300
26. Linassier C, Barin C, Calais G et al (2000) Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantron, cyclophospamide, fluorouracil and radiation therapy. Ann Oncol 11:1289-1294
27. Millefiorini E, Gasperini C, Ponzilli C et al (1997) Randomized, placebo-controlled trial of mitoxantrone in relapsing remitting multiple sclerosis. 24 month clinical and MRI outcome. J Neurol 244:153-159
28. Mistry AR, Felix CA, Whitmarsh RJ et al (2005) DNA-Topoisomerase II in therapy-related acute promyelocytic leukaemia. N Engl J Med 352:1529-1538
29. Morrisey SP, Le Page E, Edan G (2005) Mitoxantrone in the treatment of multiple sclerosis. Int MS J 12(3):74-87
30. MS Therapy Consensus Group (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis-current therapeutic recommendations. J Neurol 255:1449
31. Ottone T, Hasan SK, Montefusco E et al (2009) Identification of a potential hotspot DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer 48:213-221
32. Pascual AM, Téllez N, Bosc I et al (2010) Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler Oct 13 (in press)
33. Pedersen-Bjergaard J, Andersen MT, Andersen MK (2007) Genetic pathways in the pathogenesis of therapyrelated myelodysplasia and acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 392-397
34. Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol Mar 13(3):227-231
35. Pulsoni A, Pagano L, Lo Coco F et al (2002) Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 100:1972-1976 (Pubitemid 35001225)
36. Ravandi F (2005) Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy. Leuk Lymphoma 50(7):1073-1074
37. Erratum in: J Neurol Sci 235(1-2):79
38. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
39. Weilbach FX, Chan A, Toyka KV, Gold R (2004) The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 135(1):49-55